QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles
December 12 2022 - 4:54PM
Business Wire
Lead Independent Director Kenneth F. Buechler,
PhD, appointed non-executive Chairman Douglas Bryant to continue as
Chief Executive Officer and Director; Assumes role as President
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or
the “Company”), a global provider of innovative in vitro diagnostic
(IVD) technologies designed for point-of-care settings, clinical
labs and transfusion medicine, announced today that its Board of
Directors (the “Board”) has appointed Dr. Kenneth F. Buechler, Lead
Independent Director, to non-executive Chairman, effective December
11, 2022. The separation of the Chairman and Chief Executive
Officer roles is a key step toward strengthening the Company’s
governance practices and will facilitate the right balance between
strong and consistent Company leadership and independent oversight
by the Board. The Board also appointed Douglas Bryant to serve as
President, in addition to Mr. Bryant’s current role as Chief
Executive Officer and a member of the Board.
“On behalf of the Board, I want to thank Doug for his leadership
as both Chairman and Chief Executive Officer and the strong
execution of the transformational combination of Quidel Corporation
and Ortho Clinical Diagnostics,” said Dr. Buechler, Chairman of the
Board. “Doug has exceeded our expectations in integrating the
Company while helping the commercial team maintain its near-term
execution goals. As we look to the future, the Company has a
significant opportunity to solidify its position as a leader in the
IVD market and play a key role in meaningfully improving the global
trajectory of human health.”
“I have had the pleasure of working closely with Ken for many
years and I am pleased that I will continue to benefit from his
guidance and insights moving forward. He brings strategic oversight
combined with a wealth of leadership and scientific industry
expertise to our Board,” said Mr. Bryant, President and Chief
Executive Officer of QuidelOrtho. “With QuidelOrtho at the
forefront of developing disease-specific biomarkers and tests,
expanding centralized and point-of-care testing, changing the
technological landscape with automation, and delivering strong
performance across all business units, this is the right time for
steadfast focus on executing on our strategic priorities and
transforming the power of diagnostics into a healthier future for
all.”
Additionally, Robert J. Bujarski, Chief Operating Officer, and
Michael S. Iskra, Chief Commercial Officer, have both been
appointed to the newly created Executive Vice President roles, in
addition to serving in their existing leadership roles. “With the
exceptional leadership provided by Rob, Mike and our entire
executive team, we have never been more confident in the strategic
positioning of the Company to benefit from key market trends, the
accelerating demand for diagnostic insights and the rapidly
evolving IVD market,” concluded Mr. Bryant. View QuidelOrtho’s
executive team here.
Dr. Buechler has over 35 years of diagnostic industry expertise
and several board roles. In November 2007, he was appointed to the
board of directors of Quidel Corporation (“Quidel”) and prior to
the combination with Ortho Clinical Diagnostics served as Quidel’s
Chairman since August 2015. Dr. Buechler was previously the
co-founder of and held several scientific and research executive
roles at Biosite Inc. from 1988 until its acquisition by Alere Inc.
in 2007. Prior to co-founding Biosite, Dr. Buechler was a senior
research scientist for the diagnostics research and development
group at Hybritech Incorporated.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of
Quidel Corporation and Ortho Clinical Diagnostics behind a shared
mission of developing and manufacturing innovative technologies
that raise the performance of diagnostic testing and create better
patient outcomes across the entire healthcare continuum.
Ranked among the world’s largest in vitro diagnostics (IVD)
providers with more than 120 years of collective experience, we
combine industry-leading expertise in immunoassay and molecular
testing with a global footprint in clinical labs and transfusion
medicine.
Our Company’s comprehensive product portfolio delivers accuracy,
speed, automation and access, providing critical information when
and where it is needed most. Inspired by a spirit of service,
QuidelOrtho is committed to enhancing the well-being of people
worldwide and happy in the knowledge we are making a difference.
For more information, please visit www.quidelortho.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. You can identify these statements and other forward-looking
statements in this press release by words such as “may”, “will”,
“would”, “expect”, “anticipate”, “believe”, “estimate”, “plan”,
“intend”, “continue”, or similar words, expressions or the negative
of such terms or other comparable terminology. These statements
include, but are not limited to, QuidelOrtho’s future plans,
objectives, strategies, expectations and intentions, and other
statements that are not historical facts. Such statements are based
on the beliefs and expectations of QuidelOrtho’s management as of
today and are subject to significant risks and uncertainties.
Actual results may differ significantly from those set forth or
implied in the forward-looking statements.
The following factors, among others, could cause actual results
to differ from those set forth or implied in the forward-looking
statements: the challenges and costs of integrating, restructuring
and achieving anticipated synergies; the ability to retain key
employees; and other economic, business, competitive, and/or
regulatory factors affecting the business of QuidelOrtho generally.
Additional risks and factors are identified under “Risk Factors” in
QuidelOrtho’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (the “Commission”) on August 5,
2022, and subsequent reports filed with the Commission.
You should not rely on forward-looking statements as predictions
of future events because these statements are based on assumptions
that may not come true and are speculative by their nature.
QuidelOrtho has no obligation to update any of the forward-looking
information or time-sensitive information included in this press
release, whether as a result of new information, future events,
changed expectations or otherwise, except as required by law. All
forward-looking statements are based on information currently
available to QuidelOrtho and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221212005815/en/
Investor Contact: Bryan Brokmeier, CFA IR@Quidel.com
Media Contact media@Quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024